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The outcome of hematopoietic stem cell transplantation (HSCT) is controlled by genetic 
factors among which the leukocyte antigen human leukocyte antigen (HLA) matching 
is most important. In addition, minor histocompatibility antigens and non-HLA gene 
polymorphisms in genes controlling immune responses are known to contribute to the 
risks associated with HSCT. Besides single-nucleotide polymorphisms (SNPs) in protein 
coding genes, SNPs in regulatory elements such as microRNAs (miRNAs) contribute 
to these genetic risks. However, genetic risks require for their realization the expression 
of the respective gene or miRNA. Thus, gene and miRNA expression studies may help 
to identify genes and SNPs that indeed affect the outcome of HSCT. In this review, we 
summarize gene expression profiling studies that were performed in recent years in both 
patients and animal models to identify genes regulated during HSCT. We discuss SNP–
mRNA–miRNA regulatory networks and their contribution to the risks associated with 
HSCT in specific examples, including forkheadbox protein 3 and regulatory T cells, the 
role of the miR-155 and miR-146a regulatory network for graft-versus-host disease, and 
the function of MICA and its receptor NKG2D for the outcome of HSCT. These examples 
demonstrate how SNPs affect expression or function of proteins that modulate the allo-
immune response and influence the outcome of HSCT. Specific miRNAs targeting these 
genes and directly affecting expression of mRNAs are identified. It might be valuable in 
the future to determine SNPs and to analyze miRNA and mRNA expression in parallel in 
cohorts of HSCT patients to further elucidate genetic risks of HSCT.
Keywords: gene expression profiling, regulatory networks, non-human leukocyte antigen single-nucleotide 
polymorphisms, microRNAs, forkheadbox protein 3, miR-155, miR-146a, MiCA
iNTRODUCTiON
A considerable proportion of the risk of adverse outcome after hematopoietic stem cell transplantation 
(HSCT) is genetically determined and can be attributed to various factors including human leukocyte 
antigen (HLA) matching, killer-immunoglobulin-like receptor matching, minor histocompatibility 
antigens (miHAg), and non-HLA gene polymorphisms. Outcomes such as acute and chronic graft-
versus-host disease (aGvHD and cGvHD), relapse, and survival have been shown to be modified by 
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functionally relevant polymorphisms in non-HLA genes that are 
involved in immune responses (1, 2). Such functional polymor-
phisms are complicated to pinpoint among other polymorphisms 
localized near these genes that have no direct effects on gene 
function. Reliable identification of polymorphisms that result in 
differences in gene expression or protein function and affect the 
outcome of HSCT is challenging in view of the complexity of the 
human genome (3).
The most frequent genetic variations of the human genome are 
single-nucleotide polymorphisms (SNPs), which occur on average 
in 1 out of 300 bp throughout the genome (4–6). The majority of the 
SNPs arise in non-coding regions including intronic, intergenic, 
and untranslated regions (UTRs) (7). Those which are within genes, 
including genes affecting the immune response, may alter the 
expression of the gene or the structure of the encoded proteins (8). 
In microRNAs (miRNAs), SNPs can alter regulatory properties, 
but elucidation of the functions of these SNPs is not straight 
forward (9). Understanding the biogenesis of miRNAs is key to 
comprehending the impact of SNPs on these molecules (Figure 1). 
The miRNAs are a class of small endogenous non-coding RNAs of 
21–25 nucleotides in length that originate as primary transcripts 
(pri-miRNAs) from miRNA genes. After transcription of pri-
miRNAs by RNA polymerase II, they are processed by DROSHA, 
a RNA specific ribonuclease enzyme complex, producing short 
precursor-miRNAs (pre-miRNAs) of approximately 70 nucleo-
tides length (10). The pre-miRNAs are then transported from the 
nucleus to the cytoplasm by exportin 5 (10). In the cytoplasm, they 
undergo further cleavage by an endonuclease enzyme (DICER), 
resulting in the generation of mature miRNA (11, 12). Accordingly, 
functionally relevant SNPs can be present in miRNA biogenesis-
related genes, in specific miRNA-encoding genomic loci or in the 
seed match sequence of target mRNA 3′ UTRs. SNPs may lead 
to either an alteration in miRNA expression level, a decreased 
or increased miRNA-target interaction, or a new miRNA-target 
interaction (13). Atarod and Dickinson (14) described the driving 
gears of GvHD as miRNA’s regulating gene expression, chemokine 
and cytokine secretion, while their expression in turn is affected by 
SNPs in mRNA genes (Figure 2).
In this review, we will pinpoint SNP–mRNA–miRNA regulatory 
network alterations and their contribution to the risks associated 
with HSCT in specific examples, elucidating the consequences of 
the interaction between these three genetic elements. Moreover, 
we will summarize mRNA and miRNA profiling studies aiming 
to decipher genetic risks of HSCT.
eXAMPLeS OF SNP–mRNA–miRNA 
ReGULATORY NeTwORKS 
CONTROLLiNG OUTCOMe OF HSCT
Forkheadbox Protein 3 (FOXP3) 
Polymorphisms, mRNA expression, and 
FOXP3-Regulating miRNAs
Regulatory T  cells (Tregs) have been the focus of several HSCT 
studies due to their ability to suppress alloreactivity during GvHD 
(16). Tregs, defined as CD4+CD25+ FOXP3+ T cells, are involved 
in the maintenance of immunological tolerance (17). They reduce 
the invasion of CD8+ effector T  cells (Teff) in target tissue and 
ameliorate GvH tissue damage (18). Cuzzola and colleagues 
found an increased expression of FOXP3 mRNA in patients who 
were responsive to anti-GvHD therapies (19). These results are in 
concordance with previous data reporting an inverse correlation 
between the amount of Tregs and progression of aGvHD (20). 
Other studies showed correlation between a lower incidence 
of aGvHD and improved survival in HSCT recipients with an 
increased number of donor Tregs (21, 22). Low numbers of Tregs 
have also been associated with higher cGvHD incidence (23). 
Similarly, the severity of aGvHD and extent of cGvHD in patients 
were found to be associated with Treg numbers (24). Furthermore, 
inducing selective expansion of Tregs by the daily administration 
of low doses of interleukin (IL)-2 showed an improvement in 
clinical cGvHD symptoms in patients (25). Notably, not only 
CD4+ Tregs can mitigate GvHD but also CD8+FOXP3+ Tregs become 
induced during GvHD and can suppress the disease in mouse 
models (26, 27). CD8+ Tregs might have even advantageous over 
CD4+ Tregs since they have been reported not to abrogate graft-
versus-leukemia (GvL) effects (28). The potency of CD8+ Tregs 
cells is further emphasized by their ability to prevent the rejection 
of heart allografts in rats (29).
Currently, 90 SNPs have been identified in the FOXP3 gene 
region, and several have been identified as risk factors for a 
number of malignant and autoimmune diseases (30). An SNP 
(rs3761548) in the promoter region of FOXP3 (Figure  3) 
resulting in an A/C base exchange causes loss of binding to the 
E47 and c-Myb factors and leads to defective transcription of 
the FOXP3 gene (31). In patients undergoing HSCT, this SNP 
has been associated with a higher incidence of hepatic veno-
occlusive disease and cytomegalovirus (CMV) infection but 
a lower treatment-related mortality, resulting in a difference 
in the overall survival of patients with the CC genotype (32). 
However, the authors found no difference in the incidence of 
GvHD, relapse, or blood stream infection to be associated with 
this polymorphism (32).
Posttransplant chimerism analysis in clinical HSCT largely 
uses polymorphisms of short tandem repeats of <10 nucleotides, 
or microsatellites (Msat). They have a higher degree of allelic 
polymorphism compared to SNPs, and therefore, a larger degree 
of information (33). An Msat studied in FOXP3 is the (GT)n 
polymorphism in the promoter/enhancer region of the FOXP3 
gene (34). This polymorphism was shown to be associated with 
the development of auto- or alloimmune conditions, including 
type I diabetes, and graft rejection in renal transplant recipients 
(35). Moreover, this polymorphism has been associated with a 
lower incidence of grade III–IV GvHD in patients transplanted 
from donors carrying short alleles [≤(GT)15] (35). However, 
this polymorphism did not affect relapse, event free survival or 
overall survival in patients with aGvHD and cGvHD (35).
Recently, several miRNAs including miR-155 and miR-10a 
have been identified that impact T cell differentiation and func-
tion (36, 37). MiR-155 is required for Treg development (38) and 
for maintaining Treg homeostasis and survival by targeting SOCS1 
(39). MiR-155 is an important positive regulator of natural Treg 
(nTreg) development and miR-155 gene transcription is driven 
by FOXP3 (Figure 3) (38). In mice, miR-155 is upregulated in 
FiGURe 2 | Genetic regulation of transplant outcome. Genetic variants 
in protein encoding genes and microRNAs (miRNAs) alter gene expression as 
well as protein and cellular functions which in turn contribute to the regulating 
the outcome of transplantation. The color code introduced here is used for 
genes, miRNAs, mRNAs, and proteins in Figures 3–5.
FiGURe 1 | Regulation of microRNAs (miRNAs). Expression of miRNAs can be altered at various stages of its biogenesis by genomic [single-nucleotide 
polymorphisms (SNPs) and mutations] and epigenetic alterations. Changes in the expression and function of Drosha and Dicer, part of the miRNA processing 
machinery, lead to the deregulation of mature miRNAs. The figure has been adapted from Ref. (14, 15).
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mature Tregs (CD4+CD25+FOXP3+) relative to conventional T cells 
(CD4+CD25−FOXP3−) as well as in FOXP3+ double positive and 
single positive thymocytes (37, 40). MiR-155 knockout mice have 
reduced Treg numbers in both the thymus and periphery, and 
miR-155-deficient Tregs have a reduced proliferative potential and 
impaired IL-2 signaling (39). In this context, miR-155 promotes 
Treg survival and proliferation in the thymus and periphery by 
enhancing their sensitivity to IL-2 (39). As shown in Figure 3, 
miR-155 achieves this by targeting and downregulating SOCS1, 
an inhibitor of IL-2 signaling, thus increasing levels of activated 
STAT5 and enhancing IL-2 signaling (40). MiR-10a is function-
ally linked to stabilization of FOXP3 in Tregs (41) (Figure 3) and 
interestingly, although miR-10a has not been specifically investi-
gated in relation to HSCT, an inverse correlation between miR-
10a and susceptibility to autoimmune disease has been identified 
(41). With regard to miR-10a, it is uniquely expressed in Tregs, but 
not other T cells, where it is crucial for long-term maintenance of 
their stability and function (41). FOXP3 itself can be regulated by 
other miRNAs, including miR-21 and miR-31, which positively 
and negatively regulate FOXP3, respectively, thus having oppos-
ing effects on its expression (36) (Figure 3). MiR-31 can directly 
target FOXP3 by binding to a specific recognition site in the 3′ 
UTR region, while miR-21 regulation is believed to be indirect as 
no potential target sequence in FOXP3 was identified (36). The 
specific function of miR-21 and miR-31 in Tregs in the setting of 
HSCT is still to be explored.
The miR-155 and miR-146a Regulatory 
Network
Notably, miR-155 is involved in a larger regulatory network that 
affects the outcome of HSCT (Figure  4). Although miR-155 
FiGURe 4 | interaction between miR-146 and miR-155, their effects on 
the nuclear factor (NF)-kB pathway, and the expression of iRAK1 and 
tumor necrosis factor (TNF)-α. Activation of the NF-kB pathway 
represents a hallmark of the pathophysiology of GvHD. NF-kB activation 
induces expression of miR-146a and in turn, miR-146a inhibits these 
pathways through targeting key adapter proteins, IRAK1(⊥) and TRAF6 (⊥). 
The presence of single-nucleotide polymorphisms in coding regions of these 
genes, such as rs3027898 in IRAK1, further influences expression within the 
network. MiR-146a expression can also be stimulated by lipopolysaccharide 
(LPS) release during GvHD conditioning. The miR-146a and miR-155 
mediate an increase in TNF-α, which in turn can positively regulate miR-155 
in a feedback loop.
FiGURe 3 | interaction between microRNAs and forkheadbox protein 
3 (FOXP3) in regulatory T cells (Tregs). In Tregs, miR-10a stabilizes FOXP3, 
and FOXP3 can positively regulate expression of miR-155. This leads to a 
downregulation of the target SOCS1 (⊤), which in turn results indirectly in 
increased expression of STAT5. FOXP3 can also be regulated by miR-21, 
which indirectly positively regulates FOXP3 in a process that is not yet 
completely understood. Moreover, FOXP3 is downregulated by miR-31 by 
direct targeting of the 3′ untranslated region. To further complicate this 
regulatory network, single-nucleotide polymorphisms (SNPs) in FOXP3 also 
affect its expression in Tregs, such as the SNP rs3761548 or a GT(n) 
microsatellites (Msat).
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promotes the development of Tregs as explained above, it may 
also have pro-inflammatory functions. MiR-155 and miR-146a 
were found to be upregulated in the skin of rats suffering from 
aGVHD (42). Atarod and colleagues showed that low expression 
levels of both miR-155 and miR-146a were associated with higher 
incidence of aGVHD at day 28 post-allo-HSCT in patients and 
that both regulate expression of the transcription factor SPI1 (43). 
Pontoppidan and colleagues showed that miR-155 was increased 
in patient plasma at the time of maximal toxicity of precondition-
ing at day 7 posttransplantation and remained increased until day 
21. This was inversely mirrored by miR-146a, which was signifi-
cantly reduced from day 7 to day 21 after transplantation (44). 
Together, this suggests that miR-155 and miR-146a play opposite 
roles having pro-inflammatory and anti-inflammatory proper-
ties, respectively, and thus play a role in regulating the systemic 
inflammatory response during maximum toxicity of precondi-
tioning in HSCT patients (44). Relevantly, miR-155 expression 
was upregulated in donor T  cells in mice during aGvHD and 
mice receiving miR-155-deficient splenocytes developed less 
severe aGvHD and had increased survival rates compared to mice 
receiving wild type splenocytes (45). Specific targeting of miR-
155 using antagomirs effectively mitigated aGvHD in mice and 
increased survival rates (45). MiR-155-deficiency in the dendritic 
cell (DC) compartment also protected mice from aGvHD since 
miR-155 appears to promote the migration of DC toward sites of 
tissue damage (46). MiR-155 expression was increased in mouse 
T  cells as well as in intestinal patient biopsies during aGvHD 
(45). Expression of miR-155 can be stimulated by tumor necrosis 
factor (TNF) α (47), and similarly, miR-155 can promote TNF-α 
production in a positive feedback loop (48), thus exacerbating the 
inflammatory cascade (Figure 4). Altogether, these data indicate 
a role for miR-155 in the modulation of aGvHD.
MiR-146a is distinctly increased in response to lipopolysac-
charide (LPS), a component of the cell wall of gram-negative 
bacteria. LPS is released in response to GvHD conditioning 
regimens (Figure 4) and acts as a potent enhancer of cytokine 
secretion (49). Using a genetically engineered mouse model, 
it was demonstrated that a deletion of miR-146a results in 
several immune pathologies (50). Specifically, lack of miR-146a 
expression increased responsiveness of macrophages to LPS and 
exacerbated the inflammatory response in LPS-challenged mice. 
TNF receptor-associated factor 6 (Traf6) and IL-1 receptor-
associated kinase 1 (Irak1) genes have also been identified as 
targets of miR-146a (Figure  4), contributing to the phenotype 
of miR-146a-deficient mice (50). Both TRAF6 and IRAK1 act 
as adapter proteins in the nuclear factor (NF)-κB activation 
pathway and in addition to innate immune cells, miR-146a has 
also been shown to target these genes in T cells resulting in their 
downregulation (Figure  4). T  cells that are lacking miR-146a 
are hyperactive in both acute antigenic responses and chronic 
inflammatory autoimmune responses (51). However, the pres-
ence of SNPs in these genes that may affect miR-146a binding, 
such as rs3027898 in the IRAK1 3′UTR may further complicate 
this already complex network of interactions. Furthermore, 
activation of NF-κB has been described to upregulate miR-146a 
expression, which in turn downregulated NF-κB via TRAF6 and 
FiGURe 5 | Regulation of MiCA expression and interaction with 
NKG2D. The single-nucleotide polymorphism (SNP) rs1051792 results in a 
valine to a methionine exchange at position 129 of MICA and distinguishes 
MICA variants into those binding the receptor NKG2D with high (MICA-
129Met) or low (MICA-129Val) avidity. This polymorphism also affects the cell 
surface expression of MICA protein. The SNP rs2596542 in the promoter of 
MICA affects mRNA expression. Moreover, several microRNAs target MICA 
and downregulate its expression. Moreover, cellular and genotoxic stress 
induces the expression of MICA. The MICA receptor NKG2D is encoded by 
the KLRK1 gene and can be targeted by miR-1245.
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IRAK1 repression in a negative feedback loop (52, 53) (Figure 4). 
More recently, miR-146a regulation of TRAF6 and IRAK1 was 
specifically associated with aGvHD, since upregulation of miR-
146a expression was observed in T  cells of mice developing 
aGvHD compared to untreated mice (52). When transplanted 
with miR-146a-deficient T cells, recipient mice developed GvHD 
of increased severity resulting in reduced survival, and they 
also had elevated TNF-α serum levels (52). The protein levels of 
TRAF6 were upregulated in miR-146a-deficient T cells following 
alloantigen stimulation, and this translated into increased NF-κB 
activity. Conversely, miR-146a overexpression reduced aGvHD 
severity. In an autoimmune setting, miR-146a expression can be 
induced by TNF-α (47), which in turn is stimulated by NF-κB, 
thus further confounding this complex regulatory network 
(Figure 4). Interestingly, another member of the miR-146 fam-
ily, i.e., miR-146b, is highly expressed in CD4+CD25+FOXP3+ 
thymic-derived Tregs and has been reported to promote survival, 
proliferation, and suppressor function of these cells by targeting 
TRAF6 and subsequently increasing NF-κB activity (54).
Single-nucleotide polymorphisms within miRNA coding 
regions as well as those within their target mRNA seed regions 
can directly influence miRNA–mRNA interactions. Indeed, with 
regard to miR-146a, two SNPs rs2431697 and rs2910164 have 
been reported that cause single base changes and altered expres-
sion of the mature microRNA (Figure  4). The SNP rs2910164 
specifically results in a change from a G:U pair to a C:U mismatch 
in the stem structure of the miR-146a precursor. This results in 
processing variation and lower expression of the mature miRNA, 
which has been associated with the development of a range of 
cancers (55). Stickel and colleagues reported that the minor 
CC genotype caused a decrease in miR-146a production (52). 
The same team also provided evidence that miR-146a acts as 
an important negative regulator in murine and human GVHD, 
consistent with an anti-inflammatory role for miR-146a, and sug-
gested the exogenous increase of miR-146a as a potential novel 
strategy for therapeutic intervention in this disease (52). Further 
interactions that have been described between miRNAs and the 
induction of GvHD have been recently reviewed by Atarod and 
Dickinson (14).
MiCA Polymorphisms, mRNA expression, 
and MiCA-Regulating miRNAs
The major histocompatibility complex (MHC) class I chain-
related molecule A (MICA) is a highly polymorphic ligand for the 
activating natural killer (NK) cell receptor NKG2D (Figure 5). 
An SNP within this gene, rs1051792, which leads to an amino 
acid exchange from valine to methionine at position 129 (56), 
was investigated for its association with the outcome of HSCT. 
We found that the MICA-129Met variant was associated with an 
increased overall survival and a reduced risk to die from aGvHD, 
despite homozygous carriers of the MICA-129Val allele having an 
increased risk of developing aGvHD (57). The NKG2D pathway 
was expected to be directly related to the outcome of HSCT, since 
it is an activating receptor on NK cells (58) and a costimulatory 
receptor on CD8+ T cells (59). On the functional level, we found 
the MICA-129Met isoform triggered more cytotoxicity and 
interferon (IFN)-γ release by NK cells and it activated alloreactive 
cytotoxic T cells faster. This variant also induced more rapid and 
severe downregulation of NKG2D on NK and cytotoxic T cells 
(57). Normally, most cell types do not express MICA, but it 
becomes induced by cellular and genotoxic stress, including 
virus infection and malignant transformation. Therefore, it 
renders stressed cells susceptible to killing by NK cells and allows 
them, despite being non-professional antigen presenting cells 
(APCs), to directly activate cytotoxic T cells specific for antigens 
presented by these cells. Notably, MICA expression was found 
to be increased in GvHD-affected tissue samples from patients 
(60). The MICA-129Met variant can therefore initially confer a 
higher risk of aGvHD due to a faster activation of alloreactive 
cytotoxic T  cells (57). However, in the longer perspective, the 
strong-counter regulation of NKG2D by this variant appears to 
be associated with a decreased risk of cGvHD and an increased 
risk of relapse due to lesser GvL effects by cytotoxic T cells and 
NK cells (61).
Interestingly, the biological effects of the MICA-129 variants 
were strongly influenced by MICA expression intensity (57). The 
MICA-129Met variant triggered increased NKG2D signals at low 
expression intensities, whereas the MICA-129Val variant elicited 
more NKG2D-mediated effects at high expression intensities. At 
high expression intensity, the functional effects of the MICA-
129Met variant were impaired due to a rapid downregulation of 
NKG2D (57). Thus, MICA expression intensity could change the 
biological effect of this SNP, giving an interesting example of the 
TABLe 1 | Summary of large-scale mRNA expression profiling studies during GvHD.
Species Tissue Disease Upregulated Downregulated Technique Reference
Human Peripheral blood 
mononuclear cells 
(PBMCs)
Acute graft-versus-
host disease (aGvHD)
CXCL8, GOS2, ANXA3, NR4A2 CDKN1C qRT-PCR (92)
Human PBMC aGvHD PCDHB5, IL22RA2, PDCDILG2, IL2, PKD1 PCDHB16, IL27, IGHD, 
CCL1, CF1
Microarray (93)
Human CD4+ and CD8+ T cells Chronic graft-versus-
host disease (cGvHD)
EP300, FURIN, FNBP3, SMAD3, TGFBI, TGIF PRF1 qRT-PCR (94)
Human PBMC aGvHD TNFSF10/TRAIL, IL1RN, IFI27, GZMB, CCR5 CLK1, TNFAIP3, and 
BTG1
Microarray (95)
Human PBMC cGvHD IL21R IL18, CD28, IL17A, IL6R, PI3K IFNG, CCl1, IRAK3, 
IL12B, SOC2
Microarray (96)
Human Conjunctiva cGvHD-DE CXCL9, CXCL10, CXCL11, CXCR3 qRT-PCR (97)
Human Conjunctiva GvHD-DE IL6, IL9, IL10, CCL24, CCL28, CCL2 EGFR qRT-PCR (98)
Mouse Ear skin day 7 aGvHD Saa3, Cxcl9, Cxcl10, Ccl5, Ubd Trp1, Col1a1 Microarray (99)
Ear skin day 40 Ccl5, Saa3, Il1beta, Cxcl9 Ces3
Mouse Liver day 7 aGvHD Vcam1, Cxcl9, Gbp2, Tgtp, Tap1 Lck, Ltf Microarray (100)
Liver day 35 Ccl5, Icam1 Lck, Ltf
Mouse Liver versus kidney aGvHD Cxcl9, Cxcl10, Vcam1, Stat1, Icam1 Microarray (101)
Mouse Scla skin GvHD CXCL5, CXCL11, CXCL9, CXCL10, IL6, TGF-BR1 Cdh5, Cdh13 Microarray (102)
Rat Skin explant model aGvHD RT1-CE10 Lst1, Ubd, Aif1, RT-DMb Ly6g6e, Bat5 Microarray (103)
The listed mRNA profiling studies were carried out with human or rodent tissues obtained during both aGvHD and cGvHD. The genes regulated during GvHD with the highest fold 
changes and significant P-values are indicated.
aScl—sclerodermatous skin model of GvHD.
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complex functional interactions between SNPs and gene expres-
sion (Figure  5). Moreover, the SNP might interact with other 
SNPs in the NKG2D signaling pathway (62) including KLRK1, 
encoding NKG2D. Polymorphisms in the KLRK1 locus have been 
described also to affect the outcome of HSCT (63).
Notably, MICA expression intensities can vary for certain 
MICA alleles (64). The SNP at −1878 (rs2596542) in the 
promoter region of the MICA gene was described to affect the 
transcriptional activity (65). A polymorphic microsatellite in 
exon 5 encoding the transmembrane region of MICA modifies 
its plasma membrane expression (66). We have recently shown 
that the MICA-129Met/Val dimorphism also affects plasma 
membrane expression. Increased levels of the MICA-129Met 
variant were retained intracellularly and if expressed at the cell 
surface, the MICA-129Met variant was more prone to shedding 
than the MICA-129Val isoform (67).
Matching of donor and recipient for MICA alleles (68–71) 
and specifically for the MICA-129, polymorphism (72) has 
been found to be beneficial in HSCT, although not in all 
studies (73, 74). The effect of MICA matching appears hardly 
explainable solely by the avoidance of potential miHAg and 
further points toward an important biological function of 
MICA after HSCT.
Several stress pathways regulate the transcription of the 
MICA gene (75), and several miRNAs have been implicated in 
controlling MICA expression via posttranscriptional mecha-
nisms (Figure 5). Stern-Ginossar and colleagues described that 
the expression of MICA was decreased by miR-17, miR-20a, 
miR-93, miR-106b, miR-372, miR-373, and miR-520d (76). 
Effects of miR-17 (77), miR-20a (77–80), miR-93 (77, 80–82), 
and miR-106b (80, 81) on MICA expression have also been 
confirmed in subsequent studies. Moreover, the IFN-γ-induced 
miR-520b can lead to a reduction in MICA plasma membrane 
expression intensity (83). Interestingly, miR-520d acts on both 
the MICA 3′-UTR and the promoter region to decrease MICA 
transcript levels (83). MiR-302c and miR-520c are two further 
miRNAs that can target MICA (84). Human CMV can also target 
MICA by US18 and US20, which promote the degradation of 
MICA in lysosomes (85). The regulation of NKG2D ligands by 
miRNAs has been recently reviewed in more detail (86, 87). 
Notably, also the expression of NKG2D has been found to be 
attenuated by miRNAs, specifically, miR-1245 (88).
miRNA AND mRNA eXPReSSiON 
PROFiLiNG iN HSCT
A number of large-scale gene expression profiling studies have 
been performed in both patients and animal models to identify 
genes regulated during HSCT. In animals, both acute and chronic 
GvHD models were investigated. Studies performed on human 
samples mostly used blood or in cases of cGvHD, conjunctiva from 
patients. The advantage of using animal models for gene expres-
sion is the broad availability of specific target tissues of GvHD, 
such as liver and skin (89). A selection of the most relevant gene 
expression profiling studies is listed in Table 1. MiRNAs have also 
been studied in relation to HSCT, and there is increasing evidence 
to show that miRNAs are present in plasma, serum, saliva, urine, 
and other body fluids in a remarkably stable form that is protected 
from endogenous RNase activity (90). Circulating miRNAs have 
the potential to serve as novel and non-invasive biomarkers for 
various diseases such as cancer, cardiovascular disease, and organ 
transplant rejection and infection (91).
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miRNAs Targeting immune-Related Genes 
and Their Application on Prediction of 
HSCT Outcome
In a recent clinical study, a micro-RNA-based model was devel-
oped to predict the probability of aGvHD comprising miR-423, 
miR-199a-3p, miR-93 and miR-377. Elevated levels of these miR-
NAs were detected in plasma before the onset of aGvHD (average 
16  days before diagnosis), and their expression was associated 
with the severity of aGvHD as well as with a lower overall survival 
(91). In another profiling study of 48 miRNAs in the plasma of 
aGvHD patients, miR-586 expression was decreased upon the 
occurrence of aGvHD (104).
Interestingly, a recent publication by Wu and colleagues (105), 
which has been reviewed by Serody (106), has been shown that 
the miR-17–92 cluster, which is conserved among vertebrates, is 
important for the development of aGvHD. The miR-17–92 cluster 
is critical for the proliferation, survival and function of Th1 and 
Th17 effector T cells and inhibits Th2 and Treg differentiation (107). 
It has now also been shown that this cluster of miRNAs promotes 
the migration of CD8+ T cells to GvHD target organs and confers 
GvL effects (105). Donor T cells lacking the miR-17–92 complex 
gave rise to diminished GvHD in a mouse model of aGvHD. 
Blocking of miR-17 and miR-19b, which are included in the 
miR-17–92 complex, by systemic administration of antagomiRs 
(locked nucleic acid-modified oligonucleotides) significantly 
reduced aGvHD severity (105).
To better understand the regulation of neovascularization 
during GvHD, Leonhardt and colleagues focused on the role 
of miR-100 and showed that in intestinal tissue biopsies from 
patients undergoing allo-HSCT, miR-100 was downregulated 
when aGvHD evolved suggesting that this miRNA has a role as a 
negative regulator of aGvHD (108). MiR-100 was also downregu-
lated in the inflamed intestinal tissue of mice developing aGvHD. 
In the mouse model, functional inactivation of miR-100 with 
antagomiRs enhanced aGvHD severity, indicating a protective 
role for miR-100 by blocking inflammatory neovascularization 
during aGvHD (108).
Other studies focusing on miR-34 showed that the miR-34 
family mimics p53 effects by inducing cell cycle arrest and 
apoptosis in response to DNA damage (109). In the case of 
Fanconi anemia (FA), an inherited disorder characterized by 
developmental defects, genomic instability and progressive bone 
marrow failure (110), miR-34a expression in patient gut biopsies 
after HSCT was significantly higher in aGvHD grades II–IV 
compared to grade 0–I or with non-transplanted FA patient gut 
biopsies (111).
Association between Polymorphisms and 
Gene expression Levels in Cytokine and 
Chemokine-Coding Genes with the 
Outcome of HSCT
Cytokine Gene Expression Variation and Its Impact 
on the Outcome of HSCT
Cytokines, such as INF-γ, IL-2, and TNF-α produced by Th1 cells, 
contribute to the induction phase of aGvHD (112). A number of 
polymorphisms in genes encoding IL-10, TNF-α, and IL-6 have 
been linked to an increased risk of GvHD. IL-2 has a role as a 
T cell growth factor and treatment, and prophylaxis of aGvHD 
involves frequently inhibition of IL-2 production by cyclosporine 
A (113). Moreover, in both animal and human studies, adminis-
tration of monoclonal antibodies against the IL-2 receptor after 
HSCT have prevented aGvHD occurrence (114, 115). On the 
other hand, emerging data show that IL-2 is also necessary for 
the generation and the maintenance of CD4+CD25+Foxp3+ Tregs, 
so that inhibiting IL-2 may have a negative effect on the develop-
ment of long-term tolerance after allo-HSCT (116, 117). Another 
cytokine of critical importance during aGvHD is IFN-γ, a pro-
inflammatory cytokine, produced by several cell types such as 
activated T cells, NK, and NKT cells. IFN-γ and IL-2 both play a 
role in T cell proliferation, stimulation of cytotoxic T lymphocyte 
(CTL) and NK cell responses and production of IL-1 and TNF-α 
(118). A number of studies have reported a correlation between 
the expression of IFN-γ and severity of aGvHD (119–121). IFN-γ 
production occurs early in the cytokine cascade of GvHD. Acute 
GvHD is augmented by IFN-γ, which leads to the maturation of 
DC and stimulation of macrophages to generate cytokines and 
NO (118).
IFNG (IFN-γ) mRNA expression in the conjunctiva of patients 
was associated with dry-eye cGvHD (98) and in CD8+ T  cells 
with cGvHD (122). Ichiba and colleagues studied the regulation 
of 7,329 genes in the hepatic tissue of mice on days 7 and 35, 
after allogeneic and syngeneic bone marrow transplantation 
(100). On day 7, 456 genes and on day 35, 554 genes were regu-
lated. Interestingly, Ifng mRNA expression was not upregulated 
during hepatic GvHD on day 7 and no expression of Ifng was 
observed in the liver on day 35. However, the expression of many 
genes that are inducible by IFN-γ, such as interferon regulatory 
 factor-1 (Irf1) and Irf7 were increased (100). Both IFNG and IL2 
mRNA were increased in the peripheral blood mononuclear cells 
(PBMCs) of GvHD patients that received a donor lymphocyte 
infusion for the treatment of relapsed leukemia after allogeneic 
HSCT and IL2 mRNA expression correlated with the progression 
of GvHD (121). In another study, genes that contribute to control 
of inflammation, such as the IL-1 decoy receptor IL1R2, as well as 
pro-fibrotic genes have been found to be overexpressed in PBMCs 
of patients with cGvHD (123).
Gene expression of TNF, encoding TNF-α, a critical pro-
inflammatory cytokine, was also elevated during aGvHD in 
PBMCs of patients (93). TNF-α is one of the most important 
factors involved in the pathogenesis of aGvHD, and it is impor-
tant at various stages during the progression of the disease. The 
importance of this molecule in aGvHD was firstly described in a 
mouse model (124). Since then, several studies have shown that 
the neutralization of TNF-α can reduce symptoms of aGvHD 
(125). Tumor necrosis factor superfamily, member 10 (TNFSF10) 
mRNA expression was also elevated during aGvHD in human 
PBMCs (95).
Other cytokines regulated in GvHD include IL-15. In a 
murine aGvHD model, donor IL-15 was crucial for the devel-
opment for aGvHD (126). Investigations on the role of IL-15 
suggested that IL-15 could induce aGVHD by activating T cells 
and NK  cells (127). In conjunctiva of patients with GvHD, 
IL15 mRNA was significantly increased (98). IL27 mRNA 
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was strongly downregulated during aGvHD in PBMCs from 
patients (93). Previous reports indicate that IL-27 exhibits a 
pro-inflammatory response, is involved in activating Th1 cells, 
and enhances the immunological response to tumor cells (128). 
IL-35 is an inhibitory cytokine secreted by Tregs. The exact role of 
IL-35 in aGvHD is not known, although overexpression of IL-35 
during murine aGvHD reduced its severity by suppressing acti-
vation of effector CD4+ T cells and expansion of CD4+Foxp3+ 
Tregs in target organs of aGvHD, while preserving a GvL effect 
(129). IL-35 could be a potential therapeutic target for preven-
tion of aGvHD (129, 130).
SNPs in Cytokine Coding Genes and Association 
with HSCT Outcome
Given the dysregulation of many cytokines during acute and 
chronic GvHD, it is not surprising that SNPs in these genes have 
been associated with the outcome of HSCT. SNP association 
studies in HSCT have been recently reviewed by Dickinson and 
Norden (8). Since the original work by Middleton and colleagues 
(131), large cohort candidate gene association studies have been 
reported on SNPs in more than 20 genes that code for cytokines 
and other molecules involved in the biology of HSCT (132–135). 
Moreover, SNPs originally identified in NOD2 for their associa-
tion with Crohn’s disease have since been associated with HSCT 
outcomes (136, 137). Individuals carrying just one variant of 
rs2066844 (SNP8), rs2066845 (SNP12), or rs41450053 (SNP13) 
have a twofold to fourfold increased risk of developing Crohn’s 
disease, which increases to approximately 20-fold in individuals 
who are homozygotes or compound heterozygotes (138, 139). 
NOD2 is mainly involved in defense against infection; it recognizes 
pathogen-associated patterns and induces a cytokine response, 
and is itself regulated by pro-inflammatory cytokines (140).
Goussetis and colleagues retrospectively analyzed specific 
polymorphisms in genes for IL-10, IL-6, TNF-α, and IFN-γ in 
a pediatric cohort of 57 HLA-identical sibling myeloablative 
transplants and found a significant association between the IL10 
promoter haplotype polymorphisms at positions −1082, −819, 
and −592 with the occurrence of severe aGVHD (grades III–IV). 
Recipients with the haplotype GCC had a decreased risk of severe 
aGVHD in comparison with patients with other IL10 haplotypes 
(141). Chien and colleagues identified two SNPs in IL10, such 
as rs1800871 and rs1800872, which were associated with a 30% 
decrease of the risk for grade III–IV aGVHD (139). Moreover, 
the donor allele C for rs1800795 in IL6 was associated with a 
20–50% increase in the risk for grade II–IV aGVHD, and the IL2 
polymorphism rs2069762 in the donor genotype was associated 
with a 1.3-fold increase in risk of grade III–IV aGVHD (139).
Chemokine Gene Expression Variation and Its Impact 
on the Outcome of HSCT
Many genes encoding chemokines are regulated during GvHD. 
CXCR3 is an important chemokine receptor involved in lympho-
cyte recruitment and is expressed on T cells. CXCL9, CXCL10, 
and CXCL11, the ligands for CXCR3, are induced by the Th1 
cytokines IFN-γ and TNF-α (142). CXCL9 is expressed by effector 
CD4+ Th1 cells and CD8+ CTL and has been shown to affect the 
migration of Teff to inflamed tissue during progression of GvHD 
(142). CXCL10 and CXCL11 mRNA expression were increased in 
patient skin biopsies with aGvHD (grades II–III) when compared 
to patients without or grade I GvHD (143). The mRNA expression 
of CXCL9 and CXCL10, along with their receptor CXCR3, was 
increased in cGvHD in conjunctival biopsies of 10 patients when 
compared to 10 healthy controls (97). Elevated mRNA expres-
sion of the CXCR3 ligands, CXCL9 and CXCL10 in target organs 
of GvHD, shows that CXCR3 could have a role in GvHD (144). 
CXCL8, encoding IL-8, was upregulated in PBMC from patients 
who developed aGVHD (92). Moreover, Cxcl9 (101) and Cxcl10 
were also elevated during murine aGvHD (100). Interestingly, the 
use of CXCR3-transfected Tregs, as a novel therapeutic strategy, 
resulted in decreased severity of GvHD due to attraction of Tregs 
to the target tissues of GvHD (145).
Other chemokines involved in the stimulation and activation 
of T  cells in lymphoid tissue (Cxcl1, Cxcl2, Cxcl9, and Cxcl20, 
Ccl2, Ccl5, Ccl6, Ccl7, Ccl8, Ccl9, Ccl11, and Ccl29) and chemokine 
receptors (Ccr1 and Ccr5) were elevated in the skin of mice dur-
ing acute GvHD (99). The chemokines CCL2, CCL3, CCL4, and 
CCL5 are involved in the migration of donor cells to the target 
organs during GvHD (146). CCR5 mRNA was also increased 
during in aGvHD human PBMCs (95) and in murine skin during 
GvHD (102). In addition, Ccl2, Ccl5, Ccl17, Cxcl9 (Mig), Cxcl10 
(IP-10), and Cxcl11 (1-TAC) mRNAs were also significantly regu-
lated in mouse skin during GvHD (102). In conjunctival biopsies 
of patients with GvHD, the gene expression of CCL24, CCL18, 
and CCL2 was highly increased (98). Another chemokine mRNA, 
Ccl5 (RANTES), was elevated in the skin of mice during aGvHD 
(99) and profoundly upregulated during hepatic aGvHD (100).
Differential expression of Genes involved 
in Antigen Processing and Presentation 
during GvHD
The role of MHC molecules is of critical importance to the devel-
opment of GvHD. Both class I (HLA-A, B, and C in human) and 
class II (HLA-DR, DQ, and DP in human) determine not only 
the histocompatibility but are also responsible for controlling 
T cell recognition (147). Expression of class II HLA molecules 
by professional APCs, mainly in the gastrointestinal tract epithe-
lium and skin, allows CD4+ T cells to recognize foreign antigens, 
possibly contributing to the specific organ sites of aGvHD (148). 
During the afferent phase of the pathogenesis of aGvHD, the 
release of cytokines such as IFN-γ leads to an increased expres-
sion of MHC molecules. On day 7 of hepatic aGvHD in mice, 
MHC class II genes, including I-Aα, I-Aβ, I-Eα, and I-Eβ, were 
overexpressed and remained upregulated at day 35 of aGvHD. On 
the other hand, the expression of the MHC class I genes was not 
regulated in this study. However, the genes that encode alterna-
tive proteasome subunits and that alternate peptide production 
associated with MHC class I molecules proteasome subunit 
beta 9 (Psbm9) and Psbm8 (also known as lower molecular 
mass peptides LMP2 and LMP7) were increased in mouse liver 
during aGvHD (100). Moreover, Tap1 and Tap2 mRNAs were 
increased in mouse skin (99) as well as in liver during aGvHD 
(100). TAP1 and TAP2 are transporters associated with antigen 
processing 1 and 2, responsible for translocating peptides into the 
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endoplasmic reticulum before loading on MHC class I molecules. 
In a rat skin explant model, an increase in expression of Tap1 as 
well as Psbm8 and Ubd mRNA during graft-versus-host reaction 
was observed (103). UBD, also known as FAT10, is involved in 
the proteasomal degradation of cytosolic proteins by providing a 
ubiquitin-independent signal (149). The differential expression of 
the MHC I and II genes in addition to genes involved in antigen 
processing that have been observed during GvHD is in agreement 
with the important role of MHC genes for HSCT outcomes.
involvement of the miHAg in immune 
Responses during HSCT
Mismatches of polymorphic peptides between donor and recipi-
ents cause miHag that can also elicit an alloimmune response 
(150). The extent of the desired GvL versus the unwanted GvHD 
responses is dependent on the expression profiles of these genes. 
In humans, miHag are mostly restricted by HLA class I molecules. 
Previously, mismatches for HA-1, HA-2, and HA-5 between 
donor and recipient have been described to be associated with 
an increased risk of GvHD (151). In a gene expression profiling 
study to identify the risk of GvHD and relapse posttransplant, the 
mRNA expression of miHag was assessed in 311 HLA-matched 
siblings from a single center (152). The HA-8 gene was expressed 
in almost all tissues, whereas ACC-1 gene had a restricted profile. 
Nonetheless, both HA-8 and ACC-1 miHag mismatches were 
found to be associated with occurrence of cGvHD (152).
Notably, whole exome sequencing studies have been performed 
recently to estimate the alloreactive potential between donors and 
recipients in HSCT. It has been found that non-synonymous and 
non-conservative SNPs were twice as frequent in HLA-matched 
unrelated compared to related donor–recipient pairs (153). 
The information on SNPs between donor and recipient can be 
used to predict candidate miHags by algorithms taking peptide 
binding to HLA class I molecules and the tissue distribution of 
the respective proteins into account (154). Modeling of T  cell 
responses to these miHags potentially can help to identify more 
favorable donors or to adapt the immunosuppressive treatment 
after HSCT (155, 156).
Gene expression Patterns in T Cells 
Associated with the Outcome of HSCT
Baron and colleagues compared the gene expression profiles 
of 50 allo-HSCT donors in CD4+ and CD8+ T cells to identify 
donors that are stronger allo-responders and could elicit a 
stronger GvHD response than others could. They suggested 
genes that regulate the transforming growth factor-β signaling 
and cell proliferation, in donor T cells, as the dangerous donor 
trait responsible for the occurrence of cGvHD in the correspond-
ing recipients (94). Low levels of SMAD3 mRNA, which encodes 
a transcription factor that is activated in response to TFG-β in 
CD4+ T cells, was associated with the absence of GvHD, while 
high levels of SMAD3 were necessary but not sufficient for GvHD 
occurrence (94).
CD8+ T  cells are important effectors in aGvHD (157), and 
perforin is a cytotoxic effector protease produced by CTL and 
NK cells. High expression of perforin 1 (PRF1) mRNA in CD8+ 
T cells was found to be associated with the incidence of GVHD 
in patients (94). In the skin of mice during aGvHD, granzyme B 
(Gzmb) was significantly elevated, in addition to the downstream 
effector caspase 7 (Casp7) (99). Other genes upregulated included 
the pro-apoptotic members of the BCL2 family, BCL2-antagonist/
killer 1 (Bak1), BLC2-like 11 (Bcl2l11), and BCL2-associated X 
protein (Bax) (99). Thus, expression profiling can indicate ongo-
ing pathophysiological processes contributing to GvHD, such as 
cellular cytotoxicity.
Notably, Sadeghi and colleagues observed an increase in gene 
expression of the adhesion molecules intracellular adhesion mol-
ecule 1 (Icam1) and vascular cell adhesion molecule 1 (Vcam1) 
during murine hepatic aGvHD. Increased expression of Vcam1 
mRNA was also observed in the liver and kidney compared to 
the muscle during murine aGvHD, whereas Icam1 mRNA was 
upregulated only in the liver (101). Both adhesion molecules are 
expressed on endothelial cells and are critical for the migration 
of leukocytes to tissues during inflammation (158). Furthermore, 
Icam1 and Vcam1 genes were also upregulated in mouse skin 
during aGvHD, along with other adhesion molecules Cd18 or 
integrin subunit beta 2 (Itgb2), Ly69 or integrin beta 7 (Itgb7), 
and Psgl1 or selectin platelet ligand (Selplg) (99).
The expression of costimulatory molecules that have a role 
in regulating T cell activation, differentiation, and proliferation 
has been studied to determine their role in GvHD. CD28 and 
CD28/cytotoxic T lymphocyte antigen 4 (CTLA4) are the most 
well characterized costimulatory and inhibitory molecules, 
respectively (159). Both are present on T cells, while their ligands 
CD80 (B7-1) and CD86 (B7-2) are expressed primarily on APCs 
(160). CD28 mRNA was increased during cGvHD in PBMCs of 
patients (96). Interestingly, SNPs in CTLA4 could have an impact 
on its function. In patients, the presence of the A allele in both 
rs231775 and rs3087243 was associated with a reduced risk of 
aGvHD after HSCT (161). Another study showed that recipients 
with the +49A/G allele had a significantly lower disease-free 
survival and overall survival in comparison to recipients with 
the A/A genotype (162). In addition to the +49A/G polymor-
phism, −1722, −1661, −318 polymorphisms in CTLA4 were 
also evaluated after allo-HSCT, and a significant association 
between GA genotype (CTLA4 −1661) and GvHD was shown 
in males with GvHD compared to males without GvHD (163). In 
addition, inducible T cell costimulator (ICOS), a member of the 
CTLA4 family that is expressed on activated T cells, was shown 
to be associated with the occurrence of aGvHD (19). The exact 
role of ICOS in GvHD is not clear; however, ICOS mRNA was 
downregulated in aGvHD patients. In contrast, ICOS mRNA 
was elevated during cGvHD in activated T  cells in canines 
(164). Furthermore, blockade of ICOS in  vitro during mixed 
lymphocyte reaction (MLR) resulted in immunosuppression, 
suggesting that ICOS plays a role in graft rejection and blockade 
of ICOS could be a potential therapeutic strategy (164). Cuzzola 
and colleagues also observed an increase in mRNA expression of 
ICOS in patients responding to anti-GvHD therapies as well as 
other genes that are regulated by ICOS, including Th2 cytokines 
(IL4, STAT6, and IL18) (19).
In addition to gene and miRNA expression studies in T cells, 
the characterization of the T  cell receptor (TCR) repertoire in 
patients who underwent HSCT might be informative to assess 
FiGURe 6 | Alterations in cytokine levels, such as interleukin (iL)-10, 
iL-6, and iL-2, via immunoregulatory single-nucleotide 
polymorphisms (SNPs) can lead to altered immunoregulatory function 
of regulatory T cells (Tregs) and effector T cells (Teff). Binding of cytotoxic 
T lymphocyte antigen 4 (CTLA4) with its receptor (possibly also via functional 
single-nucleotide polymorphisms) with CD80/CD86 proteins on dendritic 
cells (DCs) can lead to induction of indoleamine 2,3 dioxygenase (IDO) and 
the catabolism of tryptophan into proapoptotic metabolites causing 
immunosuppression of Teff. Altered binding of CTLA4 may also lead to 
reduced immunosuppression via Tregs and GvHD. High IL-6 levels induced in 
DCs by Treg interaction can also cause alteration of Tregs to Th17 cells and may 
lead to exacerbation of GvHD. The figure has been taken from Ref. (170). 
Professional illustration by Alice Y. Chen.
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risks of GvHD or relapse. It has been reported recently that these 
complications were associated with a lower TCR repertoire and 
the expansion of certain T cell clones (165).
Gene expression Profiles in B Cells 
Associated with Outcome of HSCT
B  cells have been found to be important in contributing to 
cGvHD; however, the mechanisms involved in maintaining their 
activation are not known (166). Depletion of B cells reduced the 
incidence of cGvHD in mice (167). Elevated B  cell-activating 
factor (BAFF), also known as tumor necrosis factor superfam-
ily member 13b (TNFSF13B), mRNA levels were observed in 
patients with cGvHD and correlated to B cell activation (168). 
BAFF mRNA expression was also significantly upregulated in 
clinical GvHD patient biopsies in comparison to those with no 
GvHD (143). A differential pattern for gene expression for several 
genes was observed in the purified B cells from cGvHD patients 
on comparison with the B cells from healthy counterparts. Four 
of the genes, IL12A, interferon regulatory factor 4 (IRF4), CD40, 
and interferon gamma receptor 2 (IFNGR2), were downregulated 
whereas B cell linker (BLNK) mRNA was upregulated in B cells in 
patients with cGvHD (168). BLNK has been found to be impor-
tant in proliferation and survival of B lymphocytes (169).
GeNOMe-wiDe ASSOCiATiON STUDieS 
(GwAS) FOR HSCT OUTCOMe
As a result of the Human Genome and the International HapMap 
Projects in the early 2000s (4, 5), GWAS became possible, 
expanding dramatically our capacity to understand genetic vari-
ability. A GWAS study of non-HLA SNPs in allogeneic HSCT was 
reported, which identified a number of SNP genotypes associated 
with severe aGvHD using a cohort of 1,298 patient donor pairs 
(139). The IL6 donor genotype for rs1800795 was confirmed to 
be associated an increased risk of severe aGvHD. In addition 
other genes associated with aGvHD, IL2, methylene tetrahydro-
folate reductase (MTHFR), Heparanase (HPSE), and cytotoxic 
T-lymphocyte-associated protein 4 (CTLA4) were identified in 
this GWAS cohort and illustrate (Figure 6) the fact that genomic 
control of immunoregulatory cytokines could alter the function 
of cells which in turn aid or reduce successful transplant outcome 
(170).
The Ogawa group has performed GWAS study in large cohort 
involving 1,589 patients and donors to identify miHAg associated 
with aGvHD (171). They identified three new loci that were sig-
nificantly associated with severe (grade II–IV) aGvHD including 
the SNP rs17473423 within the KRAS locus. In a further GWAS 
study on a smaller identification cohort of 68 patients and a 
validation cohort of 100 patients, two GvHD susceptibility loci 
(rs17114803 and rs17114808) within the “suppressor of fused 
homolog” (SUFU) gene have been found (172). The incidence of 
aGvHD was significantly higher in patients that were homozy-
gous for CC at SUFU rs17114808, than in heterozygous patients. 
Functional studies showed that ectopic expression of SUFU in 
DCs reduced expression of HLA-DR and suppression of MLR, 
whereas an increased HLA-DR expression and enhanced MLR 
was observed on silencing of SUFU (172). In the future, GWAS 
studies in HSCT will require larger multicenter cohorts but are 
expected to reveal new genetic associations for HSCT outcomes 
(8, 147).
PROBLeMS wiTH GeNe ASSOCiATiON 
STUDieS iN HSCT
Genetic association studies have inherent difficulties when it 
comes to validation of results. Only robust genetic markers are 
able to be validated across HSCT cohorts. This is due to het-
erogeneity of transplants with regards to diagnosis, conditioning 
regimens, type of stem cells (e.g., peripheral blood, cord blood, 
or bone marrow), sibling or matched unrelated transplants and 
risk factors for outcome (CMV positivity; female to male donors, 
age of the transplant cohort) all of which alter the biology of the 
transplant itself. Problems associated with non-HLA genomics in 
HSCT have also been recently reviewed (8).
One example of this is within our own studies on SNP 
polymorphisms as risk factors for survival in chronic myeloid 
leukemia (CML). In the first study, presence of interleukin 
1 receptor antagonist (IL1RN) allele 2 genotype in the donor 
(indicating downregulation of IL-1), absence of donor IL10 
ATA/ACC genotype (indicating more downregulation of IL-10) 
and absence of tumor necrosis factor superfamily member 1B 
(TNFSF1B) 196R in the patient (indicating increased levels 
of soluble TNF-RII and decreased levels of TNF-α), all were 
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associated with decreased survival and increased transplant 
relate mortality (173). In a validation cohort of matched unre-
lated transplants, none of the SNPs could be validated, and a 
comparison of the cohorts demonstrated differences in survival 
and clinical characteristics (174).
In addition, in a larger heterogeneous cohort, including CML 
and lymphoma (2), we developed a clinical and genetic score, 
which included the European Bone Marrow Transplantation 
(EBMT) Group score. This score incorporates clinical risk fac-
tors such as age of the patient and donor; time to transplant and 
type of transplant (175–178). Using a statistical analysis that 
included a bootstrap estimate of prediction error (179, 180), three 
further SNPs were associated with survival. A protective effect 
for the IL10 genotype ACC/ACC in the donors was observed, 
while estrogen receptor 1 (ESR1) rs9340799 in the patient, IL6 
rs18000795 in the donors, and TIRAP (or MAL) rs177374 in the 
patient were associated with poorer survival (2). The subsequent 
clinical and genetic score assigned to each patient was shown to 
have a better predictive value than the EBMT score alone. In a 
more recent cohort studying acute leukemia transplant patients 
(181), three polymorphisms, presence of toll-interleukin 1 recep-
tor domain containing adaptor protein (TIRAP) (alternatively 
named MAL) allele T (rs8177374) in the patient, absence of the 
glucocorticoid receptor (GCR) haplotype (consisting of rs6198, 
rs33389, and rs33388) ACT in the patient and absence of HSPA1L 
(or HSP70-hom) +2437 (rs2227956) allele C in the patient were 
associated with decreased survival. The subsequent clinical and 
genetic score assigned to each patient was shown to have a better 
predictive value than the EBMT score alone.
Interestingly, in all cohorts, the SNPs associated with reduced 
survival were all involved in downregulating the immune 
response, suggesting that this downregulation may be linked to 
reduced GvL responses and therefore lower overall survival.
These studies indicate that although replication of the exact 
genomic profiles may be difficult to achieve, the overall influence 
of genomics on the biology of the transplant is comparable and 
leads to a similar outcome, demonstrating that genomic stud-
ies are important for understanding the overall biology of the 
transplant.
CONCLUSiON
In this review, we have shown the differential expression patterns 
of a variety of mRNA, different miRNAs and SNPs in specific 
genes that have a significant impact on transplant outcome and 
development of GvHD. In addition, several SNP–mRNA–miRNA 
regulatory networks have been found to contribute to post-
HSCT outcomes. Taken together, these findings demonstrate 
how expression of specific miRNAs can target the genes of key 
immune response modulators, directly affecting expression of 
mRNAs that influence the aGvHD response. However, mRNA 
and miRNA expression studies have not yet revealed a set of genes 
or miRNAs that can be used as reliable biomarkers for predicting 
the outcome of HSCT across different transplantation centers. 
Further, preferably multicentre, studies are required to determine 
SNPs and to analyze miRNA and mRNA expression in parallel 
in cohorts of HSCT patients to further elucidate genetic risks of 
HSCT. Such combined approaches have the potential to improve 
clinical practise of HSCT and eventually to benefit patients.
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